Barclays PLC Uro Gen Pharma Ltd. Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Barclays PLC holds 11,738 shares of URGN stock, worth $162,571. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,738

Previous 19,412 39.53%

Holding current value

$162,571

Previous $291,000 32.3%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$12.72 - $19.2 $97,613 - $147,340	-7,674 Reduced 39.53%	11,738 $197,000
Q1 2024 May 15, 2024	SELL	$13.81 - $19.33 $247,958 - $347,070	-17,955 Reduced 48.05%	19,412 $291,000
Q4 2023 Feb 15, 2024	BUY	$10.87 - $15.93 $368,993 - $540,759	33,946 Added 992.28%	37,367 $560,000
Q3 2023 Nov 07, 2023	SELL	$8.84 - $22.64 $4,243 - $10,867	-480 Reduced 12.3%	3,421 $48,000
Q2 2023 Aug 03, 2023	SELL	$8.75 - $14.29 $37,161 - $60,689	-4,247 Reduced 52.12%	3,901 $41,000
Q1 2023 May 04, 2023	SELL	$7.99 - $11.02 $51,543 - $71,090	-6,451 Reduced 44.19%	8,148 $75,000
Q4 2022 Feb 13, 2023	BUY	$7.55 - $11.96 $81,668 - $129,371	10,817 Added 286.01%	14,599 $130,000
Q2 2022 Aug 12, 2022	SELL	$5.12 - $8.74 $16,225 - $27,697	-3,169 Reduced 45.59%	3,782 $31,000
Q1 2022 May 16, 2022	SELL	$5.92 - $9.73 $121,407 - $199,542	-20,508 Reduced 74.69%	6,951 $61,000
Q4 2021 Feb 14, 2022	BUY	$9.03 - $19.13 $141,761 - $300,321	15,699 Added 133.49%	27,459 $261,000
Q3 2021 Nov 09, 2021	BUY	$14.31 - $18.39 $72,408 - $93,053	5,060 Added 75.52%	11,760 $198,000
Q2 2021 Aug 13, 2021	SELL	$15.2 - $20.94 $203,193 - $279,925	-13,368 Reduced 66.61%	6,700 $102,000
Q1 2021 May 13, 2021	BUY	$17.99 - $26.96 $170,725 - $255,850	9,490 Added 89.71%	20,068 $392,000
Q4 2020 Feb 11, 2021	SELL	$17.54 - $25.43 $43,499 - $63,066	-2,480 Reduced 18.99%	10,578 $191,000
Q3 2020 Nov 12, 2020	SELL	$18.81 - $26.42 $50,655 - $71,149	-2,693 Reduced 17.1%	13,058 $252,000
Q2 2020 Aug 12, 2020	BUY	$16.5 - $29.7 $88,555 - $159,399	5,367 Added 51.69%	15,751 $412,000
Q1 2020 May 13, 2020	SELL	$13.68 - $34.6 $128,167 - $324,167	-9,369 Reduced 47.43%	10,384 $185,000
Q4 2019 Feb 10, 2020	BUY	$21.11 - $34.86 $206,856 - $341,593	9,799 Added 98.44%	19,753 $660,000
Q3 2019 Nov 14, 2019	SELL	$23.83 - $36.44 $51,758 - $79,147	-2,172 Reduced 17.91%	9,954 $237,000
Q2 2019 Aug 14, 2019	SELL	$32.75 - $40.35 $603,811 - $743,932	-18,437 Reduced 60.32%	12,126 $436,000
Q1 2019 May 15, 2019	BUY	$35.47 - $54.55 $329,232 - $506,333	9,282 Added 43.62%	30,563 $1.13 Million
Q4 2018 Feb 14, 2019	BUY	$38.35 - $50.39 $49,126 - $64,549	1,281 Added 6.4%	21,281 $916,000
Q3 2018 Nov 14, 2018	SELL	$41.65 - $51.7 $108,290 - $134,420	-2,600 Reduced 11.5%	20,000 $945,000
Q2 2018 Aug 14, 2018	SELL	$48.35 - $65.33 $116,040 - $156,792	-2,400 Reduced 9.6%	22,600 $1.12 Million
Q1 2018 May 15, 2018	BUY	$38.64 - $57.54 $966,000 - $1.44 Million	25,000 New	25,000 $1.24 Million

Others Institutions Holding URGN

# of Institutions

119

Shares Held

39.3M

Call Options Held

158K

Put Options Held

161K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $315M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account